Pharmaceuticals
Developers of branded and generic drugs. Value creation rests on R&D pipelines, patent lifecycles, regulatory approvals and pricing power versus payers.
| Company | Last Price | Price Change | Market Cap | ||
|---|---|---|---|---|---|
|
|
|
Eli Lilly and Co
LLY
|
$987.42 |
-1.4%
|
$933.5B |
|
|
|
Johnson & Johnson
JNJ
|
$240.28 |
+0.6%
|
$578.9B |
|
|
|
Roche Holding AG
ROG
|
CHf340.5 |
-0.4%
|
$356.1B |
|
|
|
Novartis AG
NOVN
|
CHf123.08 |
+0.1%
|
$305.2B |
|
|
|
AstraZeneca PLC
AZN
|
GBX14 494 |
-0.1%
|
$303.3B |
|
|
|
Merck & Co Inc
MRK
|
$116.08 |
+0.3%
|
$288.1B |
|
|
|
Novo Nordisk A/S
NOVO B
|
kr247.25 |
-1.9%
|
$173.2B |
|
|
|
Pfizer Inc
PFE
|
$27.05 |
+0.4%
|
$153.8B |
|
|
|
Bristol-Myers Squibb Co
BMY
|
$60.13 |
+0.6%
|
$122.4B |